BONESUPPORT has completed the issuance of series C shares - Investor

The Board of Directors of BONESUPPORT HOLDING AB (”BONESUPPORT”) has, as previously communicated, on 5 March 2024 resolved issue redeemable and convertible series C shares and to, conditional upon subscription and payment from DNB Bank ASA, repurchase all issued series C-shares to secure BONESUPPORT’s obligations under the incentive program LTI 2023.

In order ensure that BONESUPPORT can fulfill its obligations under the incentive program LTI 2023 resolved by the 2023 annual general meeting, the 2023 annual general meeting authorized the Board of Directors to resolve on a directed issue of redeemable and convertible series C shares and repurchase of all issued series C shares through a directed acquisition offer to all holders of series C shares.

On 5 March 2024, the Board of Directors resolved to issue 486,840 series C shares and to, conditional upon subscription and payment from to DNB Bank ASA, repurchase all issued series C shares. DNB Bank ASA has today subscribed for all 486,840 issued series C shares, and the new share issue is completed. The subscription price per share amounted to SEK 0.625, which corresponds to the quota value of the shares.

Prior to the delivery of performance shares to employees within the BONESUPPORT Group who are participating in the incentive program LTI 2023, the series C shares will be converted into ordinary shares. Allotment of performance shares in LTI 2023 shall take place within 30 days from the publication of the year-end report for the financial year 2026.

The total number of shares in BONESUPPORT at the time of this press release amounts to 66,197,635, of which 65,055,575 ordinary shares and 1,142,060 series C shares. BONESUPPORT holds at the time of this press release no own ordinary shares and 1,142,060 own series C shares, intended for ongoing incentive programs. After the ongoing conversion of series C shares into ordinary shares and the ongoing issue of series C shares, the total number of shares will amount to 66,684,475, of which 65,719,320 ordinary shares and 965,155 series C shares, and after the ongoing transfer of ordinary shares to participants in LTI 2020 and LTI 2021 and the repurchase of series C shares as set out above, BONESUPPORT will hold no own ordinary shares and 965,155 own series C shares, intended for ongoing incentive programs.

The series C shares carry one-tenth of a vote per share and do not entitle to dividends.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.